Abstract
Introduction: Systemic treatment for neutrophilic dermatoses (ND) is challenging due to limited options and available evidence. Dapsone is an oral sulfone drug with antimicrobial and anti-inflammatory effects. It inhibits the synthesis of dihydrofolic acid. Dapsone FDA-approved indications are leprosy and dermatitis herpetiformis. Nevertheless, dapsone has been used, off-label, in a wide variety of ND. We present a case series of 15 patients with several types of ND who received treatment with dapsone.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
